FDA rejects Summit Therapeutics' lead lung cancer drug application; stock hits 52-week low
Summit Therapeutics' lead lung cancer drug application was rejected by the FDA, per Benzinga. Shares fell to a 52-week low on the news. The decision is a major regulatory setback for the company's core pipeline asset.
Source:
benzinga.com: https://www.benzinga.com/news/fda/26/11/63284061/summit-therapeutics-faces-fda-hurdle-for-lead-lung-cancer-drug-stock-tumbles
Not financial advice. For informational and educational purposes only.